CAFE Comparison of Atypicals in First Episode of Psychosis

Completed · Phase 3

Conditions studied: Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders

In brief

The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.

Key facts

Study ID

NCT00034892

Run by

AstraZeneca

Starts

2002-03-01

Expected to finish

2005-03-01

Last updated by the study team

2013-01-04

Who can join

Age: 16 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet criteria for schizophreniform disorder, schizophrenia, or schizoaffective disorder with psychotic symptoms lasting 1-60 months
• Psychotic symptoms must have persisted at least one month, and not more thn 5 years (60 months)
• Patients must have no previous history of drug treatment (greater than a total of 16 weeks) with antipsychotics

You may not qualify if…

• Patients with history of psychotic disorder with recovery period of at least 3 months
• Female patients who are pregnant or nursing
• Patients with a known history of mental retardation

Where it is running

• Study site — Stanford, California, United States
• Study site — Miami, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Augusta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Shreveport, Louisiana, United States
• Study site — Boston, Massachusetts, United States
• Study site — Worcester, Massachusetts, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — St Louis, Missouri, United States
• Study site — Las Vegas, Nevada, United States
• Study site — Brooklyn, New York, United States
• Study site — New York, New York, United States
• Study site — Butner, North Carolina, United States
• Study site — Chapel Hill, North Carolina, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Cleveland, Ohio, United States
• Study site — Kettering, Ohio, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Conroe, Texas, United States
• Research Site — Dallas, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Salt Lake City, Utah, United States
• Study site — Calgary, Alberta, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.